Company News-宜明昂科英文

Company News

Company News

Company News

A National Investigators' Meeting for the Phase III Clinical Study of ImmuneOnco's Amulirafusp Alfa (IMM0306) in Relapsed/Refractory Follicular Lymphoma Was Successfully Convened

A National Investigators' Meeting for the "Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study of IMM0306 for Injection (Amulirafusp Alfa) in Combination with Lenalidomide versus Placebo in Combination with Lenalidomide in Subjects with Relapsed/Refractory Follicular Lymphoma," sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco"), was successfully held in Harbin.

ImmuneOnco’s Subcutaneous IMM2510S IND Application Accepted, Pioneering a New Era of Bispecific Drug Delivery

This milestone marks a critical step in the formulation optimization of the IMM2510 program, promising a superior treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.

ImmuneOnco Subsidiary ImmuneCare Biopharmaceuticals Completes Enrollment for IMC-003 MAD Study, Marking New Phase in PAH Drug Development

This milestone represents a solid step forward in the clinical development of IMC-003, laying a crucial foundation for evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics under multiple dosing regimens, and holding promise to bring new hope to patients suffering from PAH.

ImmuneOnco Initiates Phase III Trial of Amouravfop Alfa (IMM0306) in Relapsed/Refractory Follicular Lymphoma

Shanghai, China, March 30, 2026 — ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco"; HKEX Stock Code: 01541.HK) today announced that the Phase III clinical trial of its in-house developed bi

ImmuneOnco Announces Phase III Study of timdarpacept (IMM01) in CMML Reaches Interim Analysis Milestone with 133 Subjects Enrolled

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces That the Phase III Study of timdarpacept (IMM01) for CMML Has Completed Enrollment of 133 Subjects, Achieving the Milestone of 132 Subjects for Interim Analysis

ImmuneOnco Receives NMPA Approval for Phase II Trial of Amouravfop Alfa (IMM0306) in Primary Membranous Nephropathy

ImmuneOnco’s Amouravfop Alfa (IMM0306) Granted NMPA Approval for Phase II Study in Primary Membranous Nephropathy

总计 98 12 3 4 5 6 7 8...16 17